Literature DB >> 35814521

Quantitative Ultrasound Assessment of Hepatic Steatosis.

Artem Kaliaev1, Wilson Chavez1, Jorge Soto1, Fahimul Huda1, Hua Xie2, Man Nguyen2, Vijay Shamdasani3, Stephan Anderson1.   

Abstract

Background/Aims: Non-alcoholic fatty liver disease (NAFLD) is widespread chronic disease of the live in humans with the prevalence of 30% of the United States population.1,2 The goal of the study is to validate the performance of quantitative ultrasound algorithms in the assessment of hepatic steatosis in patients with suspected NAFLD.
Methods: This prospective study enrolled a total of 31 patients with clinical suspicion of NAFLD to receive liver fat measurements by quantitative ultrasound and reference MRI measurements (proton density fat-fraction, PDFF). The following ultrasound (US) parameters based on both raw ultrasound RF (Radio Frequency) data and 2D B-mode images of the liver were analyzed with subsequent correlation with MRI-PDFF: hepatorenal index, acoustic attenuation coefficient, Nakagami coefficient parameter, shear wave viscosity, shear wave dispersion and shear wave elasticity. Ultrasound parameters were also correlated with the presence of hypertension and diabetes.
Results: The mean (± SD) age and body mass index of the patients were 49.03 (± 12.49) and 30.12 (± 6.15), respectively. Of the aforementioned ultrasound parameters, the hepatorenal index and acoustic attenuation coefficient showed a strong correlation with MRI-PDFF derivations of hepatic steatosis, with r-values of 0.829 and 0.765, respectively. None of the remaining US parameters showed strong correlations with PDFF. Significant differences in Nakagami parameters and acoustic attenuation coefficients were found in those patients with and without hypertension. Conclusions: Hepatorenal index and acoustic attenuation coefficient correlate well with MRI-PDFF-derived measurements of hepatic steatosis. Quantitative ultrasound is a promising tool for the diagnosis and assessment of patients with NAFLD.
© 2022 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DICOM, digital imaging and communications in medicine; HIPAA, health insurance portability and accountability act; HRI, hepatorenal index; Hgb A1C, hemoglobin A1C (glycated hemoglobin); IQ, in-phase quadrature; IR, insulin resistance; LDL, low-density lipoprotein; MRI-PDFF, magnetic resonance imaging - proton density fat-fraction; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; RF, raw radio frequency; ROI, regions of interest; SD, standard deviation; T2DM, type 2 diabetes mellitus; US, ultrasound; liver fat quantification; non-alcoholic fatty liver disease; ultrasound

Year:  2022        PMID: 35814521      PMCID: PMC9257875          DOI: 10.1016/j.jceh.2022.01.007

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  37 in total

1.  The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal
Journal:  Hepatology       Date:  2012-06       Impact factor: 17.425

2.  Hepatic Steatosis Assessment with Ultrasound Small-Window Entropy Imaging.

Authors:  Zhuhuang Zhou; Dar-In Tai; Yung-Liang Wan; Jeng-Hwei Tseng; Yi-Ru Lin; Shuicai Wu; Kuen-Cheh Yang; Yin-Yin Liao; Chih-Kuang Yeh; Po-Hsiang Tsui
Journal:  Ultrasound Med Biol       Date:  2018-04-02       Impact factor: 2.998

3.  Derivation and analysis of viscoelastic properties in human liver: impact of frequency on fibrosis and steatosis staging.

Authors:  Kathryn R Nightingale; Ned C Rouze; Stephen J Rosenzweig; Michael H Wang; Manal F Abdelmalek; Cynthia D Guy; Mark L Palmeri
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2015-01       Impact factor: 2.725

4.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study.

Authors:  Leon A Adams; James F Lymp; Jenny St Sauver; Schuyler O Sanderson; Keith D Lindor; Ariel Feldstein; Paul Angulo
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

Review 5.  The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan.

Authors:  M Sasso; V Miette; L Sandrin; M Beaugrand
Journal:  Clin Res Hepatol Gastroenterol       Date:  2011-09-15       Impact factor: 2.947

Review 6.  Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.

Authors:  D Festi; R Schiumerini; L Marzi; A R Di Biase; D Mandolesi; L Montrone; E Scaioli; G Bonato; G Marchesini-Reggiani; A Colecchia
Journal:  Aliment Pharmacol Ther       Date:  2012-12-20       Impact factor: 8.171

Review 7.  Noninvasive assessment of liver fibrosis.

Authors:  Stella M Martínez; Gonzalo Crespo; Miquel Navasa; Xavier Forns
Journal:  Hepatology       Date:  2010-11-29       Impact factor: 17.425

8.  Hepatorenal index as an accurate, simple, and effective tool in screening for steatosis.

Authors:  Richard H Marshall; Marna Eissa; Edward I Bluth; Paul M Gulotta; Nancy K Davis
Journal:  AJR Am J Roentgenol       Date:  2012-11       Impact factor: 3.959

9.  Hypertension and non-alcoholic fatty liver disease proven by transient elastography.

Authors:  Yaohui Wang; Yuhua Zeng; Changwei Lin; Zhiheng Chen
Journal:  Hepatol Res       Date:  2016-06-29       Impact factor: 4.288

10.  Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method.

Authors:  Ming-Feng Xia; Hong-Mei Yan; Wan-Yuan He; Xiao-Ming Li; Chao-Lun Li; Xiu-Zhong Yao; Ruo-Kun Li; Meng-Su Zeng; Xin Gao
Journal:  Obesity (Silver Spring)       Date:  2011-10-20       Impact factor: 5.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.